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During our characterization of plicatamide 1, a modified octapeptide: Phe-Phe-His-Leu-His-
Phe-His-dcDDOPA (where dcDDOPA 5 decarboxy-(E)-a,b-dehydro-3,4-dihydroxypheny-
lalanine) from the blood cells of the ascidian Styela plicata, we noted a series of fragment ions
from the [M 1 H]1 ion which could not be assigned. There was no evidence in the 1H NMR
spectrum to support an alternative molecular structure and the series of fragment ions were
not present in the tandem mass spectrometry analysis of the [M 1 Na]1 ion. In addition, there
was no evidence that the sample was a mixture of isobaric compounds. We propose that an
unusual C-terminal to N-terminal rearrangement is responsible for the series of fragment ions
from the [M 1 H]1 ion. This rearrangement was not observed in peptide analogs of
plicatamide which did not contain the dcDDOPA at the C-terminus suggesting that this moiety
is critical for the rearrangement. The proposed reaction is analogous to that recently reported
by Vachet et al. involving a fragment ion formed from leucine enkephalin. (J Am Soc Mass
Spectrom 2001, 12, 470–474) © 2001 American Society for Mass Spectrometry
When characterizing a peptide of unknownsequence, mass spectrometry often plays aninvaluable role. After chemical sequence
analysis has been carried out, it is generally considered
a necessity to obtain intact peptide mass analysis to
complement the chemical sequence information [3, 4].
Even more critical is the case where Edman degradation
based analysis results in only a partial sequence, or
when modified amino acids are incorporated into the
peptide sequence for which the phenylthiohydantoin
(PTH) amino acids are neither stable nor easily ana-
lyzed. In these cases, mass spectrometry often provides
the additional information required to fully characterize
the peptide. For example, unless special precautions are
taken, when g-carboxy glutamic acid [5, 6], 6-bromo-
tryptophan [7], or glycosylated residues [8] are encoun-
tered, the chemical sequence analysis for the corre-
sponding cycle is blank. In the past we have used the
high accuracy mass analysis available with Fourier
transform mass spectrometry to resolve the ambiguities
presented by the occurrence of these modified residues
[9]. Alternatively, when insufficient material is avail-
able for complete chemical sequence analysis then tan-
dem mass spectrometry (MS/MS) analysis has also
been used to complement the chemical sequence anal-
ysis [7, 10].
Ideally, when interpreting the MS/MS spectrum of
an unknown, all of the fragment ions observed would
be assigned to single bond scissions derived from the
proposed precursor structure. Clearly this is an ideal-
ized case, and quite often relatively low intensity frag-
ments are observed in the MS/MS spectrum due to
multiple bond scissions. Although multiple bond scis-
sion fragments are not generally helpful in determining
an unknown sequence, they can be reconciled with the
precursor structure once their origin is recognized [11].
However, multiple bond scission fragments are not the
only type of fragment ion that can interfere with at-
tempts to assign fragment ions. Intramolecular rear-
rangement reactions of a peptide ion occurring in a
mass spectrometer have also been observed [2, 12–14].
Fortunately, these rearrangement ions are typically of
low intensity and have been more of a curiosity recog-
nized by physical chemists concerned with understand-
ing gas phase ion reaction mechanisms.
In the pursuit of ever more sensitive mass and
MS/MS analysis instruments, electrospray ionization
has been coupled with the quadrupole ion trap mass
spectrometer. Although this configuration has proven
to have a number of significant advantages including
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sensitivity, it has also been recognized that there are
potential disadvantages with the quadrupole ion trap
[2]. The high sensitivity of this instrument in part
reflects the advantages of electrospray as a method of
converting a solution to gas phase ions and the ability of
the ion trap to capture 100’s to 1000’s of ions of specific
mass to charge ratio, and subsequently detect the 10’s to
100’s of fragment ions formed from the excitation of the
precursor ions. However, the ability to trap ions partic-
ular for extended periods of time also increases the
probability of internal rearrangement of ions [2]. As a
result, when interpreting MS/MS spectra analyzed with
ion trap instruments, multiple bond scissions and rear-
rangement ions can limit attempts to determine the
sequence of an unknown peptide. In particular, the
possibility of rearrangements which result in fragment
ions which are not consistent with the proposed pre-
cursor structure must be recognized. Here we docu-
ment a gas phase rearrangement reaction encountered
when characterizing an unknown with MS/MS.
Experimental
Mass spectra were measured by directly infusing (1–2
mL/min) the reverse-phase-high-performance liquid
chromatography (RP-HPLC) purified plicatamide sam-
ple diluted in 0.1% acetic acid in methanol (1:1) into an
Esquire (Bruker Daltonics, Billerica, MA) ion trap mass
spectrometer through an orthogonal microspray needle
based on a modified fused silica capillary (Nu-Objec-
tives, MA). The instrument was operated with 24 kV
capillary potential and 20.5 kV endplate offset. Other
conditions were standard with the exception that the
fragmentation time for controlling the residence time of
ions in the trap for the MS3 experiments (including
Figure 2) was increased from 40 to 200 ms.
Plicatamide was purified and characterized as pre-
viously described [1]. The decarboxylated dehydro
DOPA residue was found to reside on the C-terminus of
the peptide (E configuration) based on both 1H NMR
and Edman sequence analysis [1]. The homogeneity of
the plicatamide sample was determined by acetic acid
urea polyacrylamide electrophoresis (AU-PAGE) and
RP-HPLC [1]. [Tyr8] plicatamide (H-Phe-Phe-His-Leu-
His-Phe-His-Tyr-OH) was purchased from Research
Genetics and purified by RP-HPLC. [DOPA8] plicat-
amide (H-Phe-Phe-His-Leu-His-Phe-His-DOPA-OH)
was generated using a modification of the mushroom
tyrosinase catalyzed hydroxylation reaction described
by Marumo and Waite [15], the details of which will be
reported elsewhere (Taylor, unpublished results).
Results and Discussion
Figure 1 compares the MS/MS spectra of the [M 1 H]1
and [M 1 Na]1 ions of plicatamide. The MS/MS spec-
trum of the [M 1 H]1 ion contains intense series of a
and b type fragment ions as shown in Figure 1A and
Table 1. In the MS/MS of the [M 1 Na]1 ion intense
series of a, b, and y type ions were observed (see Figure
1B and Table 1). Based on the MS/MS of the [M 1 Na]1
ion together with the chemical sequence and NMR
analysis, the structure of plicatamide was determined
[1].
In the MS/MS of the [M 1 H]1 ion the intense series
of a and b type fragment ions were consistent with the
proposed structure. However, in Figure 1A, an addi-
tional series of fragment ions are observed at m/z 566.3,
679.4, 816.7, and 963.6. This series of ions cannot easily
be assigned based on the proposed structure. This series
of ions, designated “b ions” was not present in the
MS/MS of the [M 1 Na]1 ion, nor were there unas-
signed fragment ions in the MS/MS of the [M 1 Na]1
to suggest an impurity was present (see Table 1). The
mass difference between successive b3 to b6 fragment
ions was 113.1, 137.3, and 147.2 Da which corresponds
with the mass of Leu, His, and Phe residues. In addi-
tion, the mass difference between the b6 ion and the z8
ion (m/z 1100.7) was 137.1 Da which corresponded with
the mass of an His residue. Therefore the b3 to b6 and z8
ions gave the C-terminal sequence Leu-His-Phe-His
consistent with the C-terminus of plicatamide without
the C-terminal decarboxy-(E)-a,b-dehydro-3,4-dihy-
droxyphenylalanine (dcDDOPA) residue. Two possibil-
ities were considered for the origin of this series of
fragment ions: (i) that an unusual rearrangement occurs
with the C-terminal dcDDOPA residue recombining
with the N-terminal phenylalanine to form species 2
with loss of ammonia (Scheme 1) which could subse-
quently generate the b series of fragment ions or (ii) that
Figure 1. Compares the electrospray ion trap MS/MS spectra of
the (A) [M 1 H]1 and (B) [M 1 Na]1 ions of plicatamide.
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the fragmentation pattern corresponds to the MS/MS of
a C-terminally amidated derivative of species 2 (isobar-
ic with compound 1). We could exclude possibility (ii)
on the basis that no evidence for dcDDOPA bound to an
N-terminal Phe was observed in the 1H NMR spectrum,
nor was such an impurity detected by two orthogonal
methods of analysis (analytical RP-HPLC and AU-PAGE).
Based on the previous work of Vachet et al. who
observed a shift of the C-terminal residue to the N-
terminus in the leucine enkephalin a4 fragment ion that
occurred together with elimination of ammonia [2], we
propose that the C-terminal dcDDOPA residue in pli-
catamide is transferred to the N-terminus. Previously, it
was proposed that this reaction can occur either con-
certed with or stepwise after loss of NH3 from the
protonated molecule ion [2]. We carried out deuterium
exchange experiments and MS/MS measurements to
confirm the assignment of the z8 fragment ion to be due
to loss of ammonia (ND3). In addition, MS
3 analysis of
the z8 precursor shows an intense series of fragment
ions corresponding with the b series extending from b3
to b6 (see Figure 2A and Table 2). The observation of
this series of fragment ions suggests that the rearrange-
ment occurs in a concerted fashion (i.e., the m/z 1100
fragment ion has undergone almost complete rear-
rangement from the structure of z8 to that in which the
dcDDOPA residue is covalently attached to the N-
terminus of the peptide). MS3 analysis was also carried
out on the m/z 963.6 (b6) fragment ion generated from
the plicatamide [M 1 H]1. A number of intense N- and
C-terminal fragment ions (see Figure 2B and Table 2)
were observed. All fragment ions observed from the b6
precursor were consistent with expected fragments
formed from the rearranged structure, i.e., N-terminal
fragment ions contain the dcDDOPA, whereas C-termi-
nal fragment ions do not contain the dcDDOPA group
(N.B., in the case of N-terminal fragment ions, we use a
to indicate cleavage at the equivalent bond to an a type
cleavage in recognition of the fact that the rearrange-
ment has added the dcDDOPA group to the N-terminal
fragment, just as we used b to indicate b type cleavages,
otherwise the nomenclature confirms to that previously
proposed [16]. Because the C-terminal dcDDOPA resi-
due of plicatamide is already decarboxylated, we envis-
Table 1. Assignment of fragment ions observed from the MS/MS spectra of plicatamide and its analogs
Assignment
Plicatamide
[M 1 H]1
Plicatamideb
[M 1 Na]1
[DOPA8]
plicatamide
[M 1 H]1
[Tyr8]
plicatamide
[M 1 H]1
a3 404.3 426.3 — —
b3 —
a 454.3 — —
y3 1 2 — 458.2 — —
c3 1 2 — 471.3 — —
y6 1 2/a5 — 529.4 — —
a4 517.4 539.4 — —
b3 566.3 — — —
b4 — 567.3 — —
c4 1 2 563.3 584.4 — —
y4 1 2 573.3 595.4 619.0 603.2
z5 2 18 651.6 — — —
a5 654.6 676.5 655.6 654.3
b4 679.4 — — —
b5 682.5 704.4 682.6 682.4
a6 2 17 784.5 — — —
z6 2 18 788.6 — — —
y5 1 2 — 708.5 732.5 716.2
c5 1 2 — 721.4 — —
a6 801.4 823.7 801.6 801.0
b6 2 17 812.7 — — —
b5 816.7 — — —
b6 829.7 851.7 829.5 829.5
y6 1 2 — 845.6 869.4 853.4
a7 938.5 960.7 938.4 938.5
b6 963.6 — — —
b7 966.7 988.7 966.5 966.5
[M 1 H 2 45] 1072.5 1094.9 — —
[M 1 H 2 35] or
b8 2 17
1082.8 1104.9 — 1112.5
b8 1099.6 1121.8 1145.4 1129.6
[M 1 H 2 17] 1100.7
Parent 1117.5 1139.5 1163.5 1147.6
a —indicates not observed.
b All fragments from the [M 1 Na]1 species retain the Na cation replacing a proton; [M 1 H 2 35]1 and [M 1 H 2 45]1 must also involve
rearrangement from the [M 1 H 2 17]1 to enable subsequent loss of either H2O or CO, respectively.
472 CRAIG AND TAYLOR J Am Soc Mass Spectrom 2001, 12, 470–474
age that the protonated plicatamide [M 1 H]1 closely
resembles an immonium ion enabling the rearrange-
ment analogous to that observed by Vachet et al. [2]. We
note that [Tyr8] plicatamide and [DOPA8] plicatamide
do not undergo extensive loss of NH3 and that the
rearrangement to form the b series is not observed (see
Table 1). It would appear that after ionization, the
decarboxylated C-terminal protonated peptide ion is an
exceedingly reactive intermediate for rearrangement.
The comparatively long residence times of ions in the
ion trap instrument has been proposed to increase the
reaction time scale for such rearrangements [2]. We
observed that the b series of fragment ions formed from
Scheme 1. Proposed gas phase reaction scheme (A) concerted and (B) stepwise to generate
N-terminally rearranged fragment ion [2] isobaric with the z8 fragment ion.
Figure 2. Compares the electrospray ion trap MS3 analysis of the
(A) z8 and (B), b6 fragment ions generated from the plicatamide
[M 1 H]1.
Table 2. Assignment of fragment ions observed from the MS3
analysis of the z8 and b6 fragment ions generated from the
plicatamide [M 1 H]1
Assignment z8 b6
b3 566.4 566.3
a4 —
a 651.4
b4 679.4 679.6
z5 1 2 — 669.3
y5 1 1 — 682.6
x5 1 1 — 710.4
a5 — 789.0
z6 — 812.6
b5 816.6 816.6
a6 2 17 — 919.3
a6 935.4 935.4
b6 2 17 — 946.1
Not assigned 949.5 —
b6 963.6 —
a7 2 17 1056.5 —
a7 1072.5 —
b7 2 17 1083.8 —
Parent 1100.7 963.6
a —indicates not observed.
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the z8 precursor increases in intensity as the residence
time of the ions in the ion trap is extended from 40 to
200 ms. The absence of the b-series of fragment ions
from the [M 1 Na]1 ion may indicate that transfer of a
proton is critical for the rearrangement or that the
cationized precursor ion does not have sufficient energy
to surmount the activation energy barrier for the rear-
rangement reaction.
Oxidatively decarboxylated peptides two to four
residues in length have been found in a variety of
marine organisms including ascidians [17–19] and
sponges [20–23]. However, to our knowledge, plicat-
amide is the first of this class of oxidatively decarboxy-
lated peptides in which this rearrangement has been
observed. This observation may prove important for
future analysis of modified peptides and larger natural
products, in particular those containing oxidatively
decarboxylated C-terminal residues.
Conclusion
When interpreting MS/MS spectra, rearrangement ions
can limit the ability to deduce the sequence of an
unknown peptide. In particular, when carrying out the
analysis with an ion trap instrument, the possibility of
rearrangements which result in fragment ions not con-
sistent with the proposed precursor structure must be
recognized. Here we document encountering a rear-
rangement when characterizing plicatamide, a previ-
ously uncharacterized peptide with a decarboxylated
DOPA residue at the C-terminus, using MS/MS. Fortu-
itously, in this case, the rearrangement reaction had
been characterized [2] and the rearranged fragment ions
were appropriately assigned.
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